Differential responses of proliferating versus quiescent cells to adriamycin.
about
MASTL(Greatwall) regulates DNA damage responses by coordinating mitotic entry after checkpoint recovery and APC/C activationMDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblastsInhibitory phosphorylation of cyclin-dependent kinase 1 as a compensatory mechanism for mitosis exit.Salt-inducible kinase 3 is a novel mitotic regulator and a target for enhancing antimitotic therapeutic-mediated cell death.Cell-cycle regulation of the p53-inducible gene B99.Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins.Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.Complex changes in the apoptotic and cell differentiation programs during initiation of the hair follicle response to chemotherapyCo-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.Single-cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids.Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery.p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.Tetraploidization increases sensitivity to Aurora B kinase inhibition.Identification of hypermethylated genes associated with cisplatin resistance in human cancersCribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase.SGO1C is a non-functional isoform of Shugoshin and can disrupt sister chromatid cohesion by interacting with PP2A-B56Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells.A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint.Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death.Synergism between inhibitors of Aurora A and KIF11 overcomes KIF15-dependent drug resistanceBCL-W is a regulator of microtubule inhibitor-induced mitotic cell death.Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint.Depletion of p31comet protein promotes sensitivity to antimitotic drugs.Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains.G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells.A novel approach for assessing the susceptibility of Escherichia coli to antibiotics.Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.ING1b decreases cell proliferation through p53-dependent and -independent mechanisms.Ultrasound: a chemotherapy sensitizer.Degradation of Cyclin A Does Not Require Its Phosphorylation by CDC2 and Cyclin-dependent Kinase 2
P2860
Q27336474-51D161DB-C65D-4E11-83DA-0515363FFCFAQ28200748-60D2B5BB-D5AC-4060-AD39-3D8C0D72BAF0Q30502423-4377B263-7C50-4598-95C2-76D4F158FC08Q30577179-99D9946F-CD1F-49EA-949C-61E85E75ACEFQ33917677-E76D4973-3BD4-48BF-B947-0418D98B64D6Q34139354-8CF06717-7DB7-4269-8489-DBAEA8BD6CCEQ34164261-CDFACC1F-8817-49D0-9FB7-FA23052B3FBEQ34221455-970F528A-42D2-4188-91E0-D1CBBA90554AQ34490533-118AA60A-2CE2-46EF-8DB4-149B6823F51DQ35832355-B8AB3DEA-3905-4003-B435-49CF3C19996FQ36356243-94E51EFB-FAB2-4B1C-879A-61359B8198A2Q37165395-A5C8F2D2-939A-4AC3-A6BA-723AEC05D170Q37433585-F4480CDE-2048-4780-A7F7-D971443B8BCFQ38320058-4947432B-62B7-4485-A43B-AB2643D957D5Q39108757-1380D96C-0D98-4058-BCD3-7D961AB79924Q39327085-2AC0F336-F9CA-489B-9498-EB66841919E3Q39730118-10BE4F2A-3CAE-48C1-AB2A-5641791D88A9Q39737530-5BD0E0DD-7E9B-4F04-B506-F4B664C8FC71Q39938210-5F705256-EE06-43B8-A064-6941BE76EB6AQ39987787-9A92391F-E977-4AFC-A699-D52BDB9BBCFAQ40248130-46B6CF03-523F-4E42-A28D-952C0CA1C609Q40391825-B075E6FA-908D-4C3A-B2AB-76C1A793C9E2Q40446144-8598FE97-5C0B-4509-9993-21E9923E009CQ40860037-97942DA6-0FCB-4503-839A-7B872439B3EAQ41135294-DBEB3B46-A79E-4FC5-A22A-A805931345F6Q41887304-253D0CBF-9B99-41C0-BC64-18315BA7933BQ41923223-81CABA4A-0E37-4C73-998D-D3AFB02B9A85Q42063551-67AFA047-B6A3-4827-A555-3828AD6831E7Q42454455-EF2D32FD-54E2-47D4-ADFC-507E60A31A92Q42808556-6C368808-A944-4FA8-8D47-C4F2A6943A7DQ42838150-46882AB0-8DC5-483E-BA5F-A5C68995CB61Q43084851-3E5E7026-3152-4FF7-A7DB-21B9F0BA4E72Q44448455-096A0535-FD2D-488C-ABE9-9DC9C34BB296Q44627967-CCBCF397-BD28-4228-8DC6-B5E0A78DB1FCQ46897351-328B4275-61C8-4274-A8B8-0556E063B647Q58327599-8B45440C-104D-4186-91FB-EF88E771946D
P2860
Differential responses of proliferating versus quiescent cells to adriamycin.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Differential responses of proliferating versus quiescent cells to adriamycin.
@en
Differential responses of proliferating versus quiescent cells to adriamycin.
@nl
type
label
Differential responses of proliferating versus quiescent cells to adriamycin.
@en
Differential responses of proliferating versus quiescent cells to adriamycin.
@nl
prefLabel
Differential responses of proliferating versus quiescent cells to adriamycin.
@en
Differential responses of proliferating versus quiescent cells to adriamycin.
@nl
P356
P1476
Differential responses of proliferating versus quiescent cells to adriamycin.
@en
P304
P356
10.1006/EXCR.1999.4551
P407
P50
P577
1999-07-01T00:00:00Z